옵션 체인은 다양한 행사가격과 만기일에 대한 BioXcel Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 BioXcel Therapeutics에 대한 시장 심리를 평가합니다..

BioXcel Therapeutics (NASDAQ:BTAI) 주식, 옵션 체인

BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $5 to $3.

News

Price Target

Analyst Ratings

BTAI

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $3

Shares of Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) rose sharply in today's pre-market trading after the company provided <a href="https://www.benzinga.com/news/earnings/25/01/43179578/twilio-stock-is-trading-higher-after-hours-whats-going-on">preliminary financial results for the fourth quarter.</a>
After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing. The company said it now expects fourth-quarter revenue growth of approximately 11% year-over-year, up from prior guidance of 7% to 8%.
Twilio shares jumped 18.5% to $134.40 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 87.6% to $6.94 in pre-market trading after the company announced its intention to initiate a clinical study combining its Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) gained 76.4% to $0.8999 in pre-market trading after dropping around 18% on Thursday. Starbox Group recently announced the launch of its StarboxAI-IntelliContentCreate platform.</li>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) rose 55% to $5.64 in pre-market trading after jumping 53% on Thursday. Evaxion recently said it completed dosing in phase 2 trial with personalized cancer vaccine EVX-01.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) gained 44.6% to $19.30 in pre-market trading after jumping 377% on Thursday. Dogwood Therapeutics recently announced patient dosing for its Phase 2b trial evaluating halneuron will commence in the first quarter.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) rose 27.1% to $0.0549 in pre-market trading. Aclarion recently announced the pricing of $14.4m public offering of common stock and warrants.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 25.5% to $1.87 in pre-market trading after the company announced it regained Nasdaq compliance regarding the minimum bid pricing list requirement.</li>
<li>BioXcel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) gained 21.5% to $0.4616 in pre-market trading after gaining over 4% on Thursday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 17.5% to $0.57 in pre-market trading after the company launched the LaunchBox monitor in Canada.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) rose 14.2% to $20.99 in pre-market trading following a 5% decline on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hyzon Motors Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) fell 46% to $0.4172 in pre-market trading. Hyzon Motors, last month, issued a worker adjustment and retraining notification and cited the inability to raise funding and uncertainty related to the availability of government subsidies.</li>
<li>Centessa Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) shares fell 38.5% to $10.01 in pre-market trading.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 29.8% to $7.20 in pre-market trading.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 28.1% to $0.9999 in pre-market trading after jumping more than 5% on Thursday.</li>
<li>DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) shares fell 18.4% to $5.61 in pre-market trading after gaining over 3% on Thursday.</li>
<li>First Financial Bancorp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) dipped 13.8% to $24.11 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) fell 13.4% to $0.0433 in pre-market trading. Conduit Pharmaceuticals shares dipped 20% on Thursday after the company board approved a 1-for-100 reverse stock split.</li>
<li>Valens Semiconductor Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) declined 12% to $2.58 in pre-market trading after declining 3% on Thursday.</li>
<li>Acacia Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) fell 11.7% to $3.86 in today's pre-market trading.</li>
<li>PB Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBBK#NASDAQ">PBBK</a>) shares dipped 10% to $13.59 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

Offerings

BioXcel Therapeutics Files For Resale Of Up To 5.1M Shares By The Selling Stockholders

WIIM

BioXcel Therapeutics shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform and cut its price target from $7 to $0.25.

B of A Securities analyst Geoff Meacham downgrades BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) from Buy to Underperform and lowers the price target from $7 to $0.25.

Downgrades

B of A Securities Downgrades BioXcel Therapeutics to Underperform, Lowers Price Target to $0.25

BioXcel Therapeutics shares are trading higher. Canaccord Genuity maintained a Buy rating on the stock.

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $7 to $5.

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 41.7% to $15.39 during Friday's pre-market session. The company's market cap stands at $33.4 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock rose 34.76% to $0.79. The market value of their outstanding shares is at $6.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock moved upwards by 23.07% to $13.6. The company's market cap stands at $930.4 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 20.27% to $1.78. The company's market cap stands at $2.2 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 12.58% to $3.4. The market value of their outstanding shares is at $2.9 million. As per the press release, Q3 earnings came out today. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 12.56% to $0.77. The company's market cap stands at $50.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock decreased by 55.0% to $6.08 during Friday's pre-market session. The company's market cap stands at $7.0 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 17.01% to $4.44. The company's market cap stands at $1.5 billion. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares decreased by 14.42% to $0.95. The market value of their outstanding shares is at $107.1 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares decreased by 8.87% to $0.52. The company's market cap stands at $22.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 7.93% to $0.29. The company's market cap stands at $4.2 million. </li>
<li>TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) shares declined by 7.88% to $14.75. The market value of their outstanding shares is at $220.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

IOBT

LIFW

PROC

REPL

SCNI

SLXN

TBRG

VRPX

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

BioXcel Therapeutics shares are trading lower after the company announced a public offering valued at $7 million consisting of shares and warrants.

Including Pre-Funded Warrants For Up To 9M Shares,&nbsp;

BioXcel Therapeutics Prices $7M Public Offering Of 5.6M Shares And Warrants At $0.48 Per Unit; With Proceeds Supporting Neuroscience And Immuno-Oncology Development Efforts

The Company intends to use the net proceeds of this offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.
 &nbsp;

BioXcel Therapeutics Commences Public Offering Of Shares Of Its Common Stock And Accompanying Warrants; No Terms Disclosed

BioXcel Therapeutics shares are trading lower after the company reported worse-than-expected Q3 revenue results.

BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.60) by 46.67 percent. This is a 81.4 percent increase over losses of $(1.72) per share from the same period last year. The company reported quarterly sales of $214.00 thousand which missed the analyst consensus estimate of $1.31 million by 83.61 percent. This is a 37.24 percent decrease over sales of $341.00 thousand the same period last year.

Earnings

BioXcel Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.60) Estimate, Sales $214.00K Miss $1.31M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.
Analysts estimate that BioXcel Therapeutics will report an earnings per share (EPS) of $-0.52. 
The market awaits BioXcel Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.50, leading to a 5.06% drop in the share price on the subsequent day.
Here's a look at BioXcel Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.71</td>
<td>-0.70</td>
<td>-0.91</td>
<td>-1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.87</td>
<td>-0.76</td>
<td>-1.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731510157_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of BioXcel Therapeutics were trading at $0.665 as of November 12. Over the last 52-week period, shares are down 84.48%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BTAI/earnings">To track all earnings releases for BioXcel Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: BioXcel Therapeutics's Earnings Preview

SERENITY At-Home Pivotal Phase 3 trial
<ul>
<li>Designed to evaluate the safety of a 120 mcg dose of BXCL501 in the at-home setting for agitation associated with bipolar disorders or schizophrenia
<ul>
<li>The first patient has been randomized.</li>
<li>The Company&nbsp;announced <a href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-initiation-serenity-home-pivotal">trial initiation</a> on September 5, 2024, with an expected trial duration of 9 to 12 months.</li>
<li>The double-blind, placebo-controlled, 12-week outpatient trial is expected to enroll approximately 200 patients residing at home.</li>
</ul>
</li>
</ul>
TRANQUILITY In-Care Pivotal Phase 3 trial
<ul>
<li>Designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for AAD over a 12-week period
<ul>
<li>Received feedback from the U.S. Food and Drug Administration on proposed protocol</li>
<li>The double-blind, placebo-controlled study trial is expected to enroll a total of approximately 150 patients aged 55 years and older across the spectrum of Alzheimer's disease severity with mild, moderate, and severe dementia with mini-mental state examination (MMSE) scores of 0 to 25 who reside in skilled nursing facilities, memory care units, or assisted living facilities.</li>
<li>The trial is expected to enroll patients with episodic agitation, with patients self-administering 60 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.</li>
<li>The planned primary endpoint is a change from baseline in the Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score at two hours post-first dose. This is the same endpoint used in previous TRANQUILITY trials and in studies that supported the FDA approval of IGALMI&#x2122; (dexmedetomidine) sublingual film.</li>
<li>Continued efficacy evaluations are expected to be conducted through performing additional PEC and complementary efficacy measures, including the global impression of change in agitation.</li>
</ul>
</li>
</ul>

Biotech

Health Care

General

BioXcel Therapeutics Announced The Achievement Of Clinical And Regulatory Progress For Its Pivotal Phase 3 Trials Of BXCLl501 For The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia (SERENITY At-Home) And Agitation Associated With Alzheimer's Dementia (TRANQUILITY In-Care)

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $7 to $5.

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

BioXcel Therapeutics Reports Department Of Defense Grant To University Of North Carolina To Fund Study Of BXCL501; Phase 2a Efficacy And Safety Trial Enrollment Initiation Expected In H1 2025

Bioxcel Therapeutics Will Reduce Its Workforce By 15 Employees, Or Approximately 28% Of The Company's Headcount-Filing

Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure

BioXcel Therapeutics announces pricing of $7M public offering

Canaccord lowered the firm's price target on BioXcel Therapeutics (BTAI) to $5 from $7 and keeps a Buy rating on the shares. The firm updated its m...

BioXcel Therapeutics price target lowered to $5 from $7 at Canaccord

Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) and decreased the price tar...

Bioxcel Therapeutics: Strategic Initiatives and Market Opportunities Drive Buy Rating Amid Financial Challenges

BofA analyst Alec Stranahan downgraded BioXcel Therapeutics (BTAI) to Underperform from Buy with a price target of 25c, down from $7. The firm cite...

BioXcel Therapeutics downgraded to Underperform from Buy at BofA

Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. BioXcel Therapeutics announced amendments to the employment agreements of its key ex...

Bioxcel Therapeutics Revises Executive Compensation Structure

BioXcel Therapeutics files to sell 5.1M shares of common stock by selling shareholders

16:47 EST BioXcel Therapeutics (BTAI) files to sell 5.1M shares of common stock for holders Published first on TheFly – the ultimate source for rea...

BioXcel Therapeutics files to sell 5.1M shares of common stock for holders

Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. On January 15, 2025, BioXcel Therapeutics increased its Board of Directors from seve...

Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target of ...

H.C. Wainwright Remains a Buy on Bioxcel Therapeutics (BTAI)

ATXI

ELAB

LTRN

MSFT

RNAZ

TVGN

WINT

Press Releases

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Financing

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

IPOs

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Aprea Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Comments

BioXcel Therapeutics

BioXcel Therapeutics (BTAI) 옵션

BioXcel Therapeutics (NASDAQ:BTAI) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌